Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 3/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19614658 | 0.85 | DUT (0.55) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL19636698 | 0.85 | DUT (0.55) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL19614665 | 0.85 | DUT (0.55) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL19614657 | 0.85 | DUT (0.55) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL19636703 | 0.85 | DUT (0.55) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL17560698 | 0.85 | DUT (0.54) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL21418793 | 0.85 | DUT (0.54) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL23066268 | 0.84 | DUT (0.53) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL16777673 | 0.84 | DUT (0.53) | DUTP2RY2P2RY4POLA1TOP2A | |
| SCHEMBL18475789 | 0.81 | DUT (0.51) | DUTP2RY2P2RY4POLA1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8969535-B2 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2125856-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090081686-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2008070749-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | DUT 23/4885P2RY2 1089/4885P2RY4 588/4885 |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | UNG, NT5C3B, OGG1 | DUT 17/4885P2RY2 974/4885P2RY4 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.